8-K: SeaStar Medical Secures $4M in Public Offering, Implements Cost Cuts to Bolster Nasdaq Compliance

SeaStar Medical announced the pricing of a public offering to raise up to $8 million, alongside significant cost-cutting measures and liability restructuring, to regain and maintain Nasdaq listing compliance.

Summary

• SeaStar Medical commenced a best efforts public offering on June 20, 2025, which closed on June 23, 2025.
• The offering included 4,935,385 shares of common stock, 1,218,462 pre-funded warrants, and 6,153,847 Series A and 6,153,847 Series B warrants.
• The combined offering price for each Share and accompanying Common Warrants was $0.65, and for each Pre-Funded Warrant and accompanying Common Warrants was $0.6499.
• The company expects net proceeds of approximately $3.39 million from the offering, excluding proceeds from warrant exercises.
• Gross proceeds from the offering are approximately $4 million upfront, with potential additional gross proceeds of approximately $4 million if Series B short-term warrants are fully exercised.
• The net proceeds are intended for general corporate purposes, including costs associated with being a public company.
• On June 17, 2025, the Board of Directors approved a 20% decrease in the annual base salaries of the CEO, CFO, and CMO, as well as certain other management members, and a 20% reduction in director cash retainer fees.
• These cost reductions are expected to reduce monthly operating expenses by approximately $50,000.
• In May and June 2025, approximately $1.2 million of employee compensation and Director fee liabilities were extinguished through waivers.
• The company believes it is in compliance with Nasdaq's $2,500,000 stockholders equity requirement as of the report date, following revenue generation, expense reduction, liability restructuring, and fundraising.
• SeaStar Medical had previously received a Nasdaq notification on June 24, 2024, for non-compliance with the $35 million minimum market value of listed securities requirement.
• On December 24, 2024, Nasdaq notified the company of continued non-compliance, making its securities subject to delisting.
• On March 11, 2025, the Nasdaq Hearings Panel granted an exception until June 22, 2025, for the company to demonstrate compliance with the stockholders equity requirement.
• In the second fiscal quarter, the company increased its customer count to six for its FDA-approved product, QUELIMMUNE, which is used by ICU physicians treating pediatric patients with multiple organ failure.

Sentiment

Score: 6

Explanation: The document presents a mixed bag. While the company successfully raised capital and took decisive steps to address Nasdaq compliance and reduce expenses, the need for such drastic measures (salary cuts, liability waivers, repeated capital raises) and the prior Nasdaq non-compliance indicate underlying financial challenges. The positive clinical and regulatory progress (FDA approval, Breakthrough Designation, customer growth) provides a strong foundation, but the immediate financial situation remains precarious, with funding only secured through November 2025.

Positives

• Successfully priced and closed a public offering, securing approximately $4 million upfront and potential additional $4 million from warrant exercises.
• Implemented a cost-cutting program, including a 20% reduction in CEO, CFO, CMO salaries and director fees, expected to save $50,000 monthly.
• Extinguished approximately $1.2 million in employee compensation and director fee liabilities through waivers.
• Increased customer count to six for its FDA-approved QUELIMMUNE product in the second fiscal quarter.
• Believes it is now in compliance with Nasdaq's $2,500,000 stockholders equity requirement, addressing a previous non-compliance issue.
• QUELIMMUNE has been shown to reduce pediatric mortality by approximately 50% and completely relieve pediatric patients from a lifetime of dialysis.
• SeaStar's Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA.

Negatives

• The company previously failed to maintain Nasdaq's minimum market value of listed securities ($35 million) and received delisting notifications.
• The need for a public offering and the associated warrant issuances indicate ongoing capital requirements and potential significant dilution for existing shareholders.
• Management and director salary cuts, along with liability waivers, suggest financial challenges and a need for aggressive cost management.
• The company expects to incur losses in the second quarter.

Risks

• Risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates.
• Risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including current or future clinical trials.
• Risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators.
• Risk that SeaStar Medical may never achieve or sustain profitability.
• Risk that SeaStar Medical may not be able to access funding under existing agreements.
• Risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations.
• Risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical's products and services.
• Risk that SeaStar Medical is unable to secure or protect its intellectual property.
• Market and other conditions affecting the company.
• Risk that SeaStar Medical is unable to maintain compliance with Nasdaq's continued listing requirements.
• Risks related to the completion of the public offering.
• Risks related to the potential exercise of warrants.
• Volatility of the stock market in general and the common stock in particular.

Future Outlook

The company expects the net proceeds from the offering, combined with existing cash, to fund its planned operations through November 2025. They also anticipate reducing monthly operating expenses by approximately $50,000 due to cost-cutting measures, which are not expected to materially impact operations. The company is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy.

Management Comments

• "The Company believes that the net proceeds from the Offering, together with its cash and cash equivalents, will be sufficient to fund its planned operations through November 2025."
• "We do not anticipate that these expense reductions will have a material impact on operations."
• "We believe that, as of the date of this report, the Company is in compliance with the Equity Rule."

Industry Context

SeaStar Medical operates in the critical care healthcare sector, specifically targeting organ failure with its FDA-approved QUELIMMUNE product for pediatric AKI and its SCD therapy for adult AKI. The company's focus on "Breakthrough Device Designation" highlights its strategy to accelerate market access and reimbursement for innovative, high-unmet-need medical devices, a common trend for companies developing novel therapies in complex disease areas. The capital raise and cost-cutting measures reflect the typical challenges faced by commercial-stage biotech/medtech companies in funding operations and clinical trials while striving for profitability.

Comparison to Industry Standards

• QUELIMMUNE (SCD-PED) is noted as the "only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients." This indicates a unique market position with no direct comparable FDA-approved products for this specific indication.
• The company's SCD therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, which is a significant regulatory achievement, similar to designations received by other innovative medical device companies (e.g., Medtronic, Edwards Lifesciences for novel cardiovascular devices) aiming for expedited review and favorable reimbursement.
• The pivotal trial for SCD therapy in adult AKI patients requiring continuous renal replacement therapy addresses a "life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually," suggesting a large unmet need comparable to other high-impact medical conditions targeted by companies like Baxter (renal care) or Fresenius Medical Care (dialysis), though SeaStar's approach is distinct.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Experience dilution from the public offering and warrant issuances. Benefit from the company's efforts to regain Nasdaq compliance, potentially preventing delisting. May see improved financial stability due to cost reductions and capital raise.
• Employees: Key management (CEO, CFO, CMO) and other management members experienced a 20% salary reduction. Some employees waived accrued bonuses, extinguishing liabilities. This indicates a shared burden in cost-cutting efforts.
• Customers: Continued advancement of the business plan and increased customer count for QUELIMMUNE suggests ongoing product availability and support for pediatric patients.
• Creditors: Extinguishment of approximately $1.2 million in accrued liabilities (employee compensation and director fees) improves the company's balance sheet and financial health, potentially benefiting creditors.

Next Steps

• Fund planned operations through November 2025 using net proceeds from the offering and existing cash.
• Continue cost-cutting program for the remainder of the fiscal year.
• Continue advancing business plan, including increasing customer count for QUELIMMUNE.
• Continue pivotal trial of SCD therapy in adult patients with AKI.
• Maintain compliance with Nasdaq's continued listing requirements.

Key Dates

Recommendation

Keywords

SeaStar Medical, ICU, Nasdaq, Public Offering, Common Stock, Warrants, Pre-funded Warrants, Capital Raise, SEC Filing, 8-K, Financial Health, Cost Reduction, Corporate Governance, Nasdaq Compliance, QUELIMMUNE, SCD-PED, Acute Kidney Injury, Pediatric Mortality, FDA Approval, Breakthrough Device Designation, Healthcare, Medical Devices, Organ Failure